{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:14:50Z","timestamp":1774566890323,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2002,7,1]],"date-time":"2002-07-01T00:00:00Z","timestamp":1025481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2002,7]]},"DOI":"10.1067\/mai.2002.124771a","type":"journal-article","created":{"date-parts":[[2002,10,9]],"date-time":"2002-10-09T21:24:11Z","timestamp":1034198651000},"page":"45-50","source":"Crossref","is-referenced-by-count":19,"title":["Switching from conventional to extrafine aerosol beclomethasone dipropionate therapy in children: A 6-month, open- label, randomized trial"],"prefix":"10.1067","volume":"110","author":[{"given":"Stanley J.","family":"Szefler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Warner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris","family":"Staab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Wahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muriel","family":"Le Bourgeois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth E.M.","family":"van Essen-Zandvliet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujata","family":"Arora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f8ren","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1067\/mai.2002.124771a_bib1","first-page":"91","article-title":"Improved performance characteristics of CFC-free aerosol MDIs","volume":"8","author":"June","year":"1995","journal-title":"J Aerosol Med"},{"key":"10.1067\/mai.2002.124771a_bib2","first-page":"A33","article-title":"Lung deposition of coarse CFC vs fine HFA pMDI aerosols of beclomethasone dipropionate (BDP) in asthma","volume":"161","author":"Dolovich","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1067\/mai.2002.124771a_bib3","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1183\/09031936.98.12061346","article-title":"Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone","volume":"12","author":"Leach","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1067\/mai.2002.124771a_bib4","first-page":"S342","article-title":"Systemic safety of HFA-BDP extrafine aerosol: comparison with conventional CFC-BDP","volume":"107","author":"Boulet","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1067\/mai.2002.124771a_bib5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1081-1206(10)62905-5","article-title":"Long-term safety and efficacy of a CFC-free beclomethasone dipropionate extrafine aerosol","volume":"86","author":"Fireman","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1067\/mai.2002.124771a_bib6","doi-asserted-by":"crossref","first-page":"S250","DOI":"10.1016\/S0091-6749(99)70041-2","article-title":"Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans","volume":"104","author":"Leach","year":"1999","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl 25","key":"10.1067\/mai.2002.124771a_bib7","first-page":"237s","article-title":"Breath-actuated CFC-free beclomethasone dipropionate inhaler is bioequivalent to well coordinated MDI","volume":"10","author":"Soria","year":"1997","journal-title":"Eur Respir J"},{"issue":"suppl 25","key":"10.1067\/mai.2002.124771a_bib8","first-page":"236s","article-title":"HFA-beclomethasone provides equivalent lung deposition with or without add-on spacers","volume":"10","author":"Leach","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1067\/mai.2002.124771a_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0954-6111(99)90073-2","article-title":"Acute safety of beclomethasone dipropionate in a new CFC-free propellant system in asthmatic patients","volume":"93","author":"Ayres","year":"1999","journal-title":"Respir Med"},{"key":"10.1067\/mai.2002.124771a_bib10","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/BF00194337","article-title":"Acute safety of the CFC-propellant HFA-134a from a pressurised metered dose inhaler","volume":"48","author":"Donnell","year":"1995","journal-title":"Eur J Clin Pharmacol"},{"issue":"suppl 6","key":"10.1067\/mai.2002.124771a_bib11","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.2042-7158.1996.tb05980.x","article-title":"Twenty-eight day double-blind safety of an HFA-134a inhalation aerosol system in healthy subjects","volume":"48","author":"Harrison","year":"1996","journal-title":"J Pharm Pharmacol"},{"key":"10.1067\/mai.2002.124771a_bib12","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0091-6749(99)70016-3","article-title":"Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant","volume":"104","author":"Busse","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1067\/mai.2002.124771a_bib13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1742-1241.1999.tb11741.x","article-title":"Switch to non-CFC inhaled corticosteroids: a comparative efficacy and safety study of HFA-BDP and CFC-BDP metered dose inhalers","volume":"53","author":"Demedts","year":"1999","journal-title":"Int J Clin Pract"},{"issue":"suppl A","key":"10.1067\/mai.2002.124771a_bib14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0954-6111(98)90214-1","article-title":"HFA-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to CFC beclomethasone dipropionate at approximately half the total daily dose","volume":"92","author":"Davies","year":"1998","journal-title":"Respir Med"},{"key":"10.1067\/mai.2002.124771a_bib15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1378\/chest.115.2.343","article-title":"Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma","volume":"115","author":"Gross","year":"1999","journal-title":"Chest"},{"issue":"suppl A","key":"10.1067\/mai.2002.124771a_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0954-6111(98)90215-3","article-title":"Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol","volume":"92","author":"Thompson","year":"1998","journal-title":"Respir Med"},{"key":"10.1067\/mai.2002.124771a_bib17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1053\/rmed.1999.0772","article-title":"Equivalent asthma control after dose reduction with HFA-134a beclomethasone solution aerosol. Comparative Inhaled Steroid Investigation Group (CISIG)","volume":"94","author":"Magnussen","year":"2000","journal-title":"Respir Med"},{"key":"10.1067\/mai.2002.124771a_bib18","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1542\/peds.109.6.e92","article-title":"Growth, systemic safety, and efficacy during one year of asthma treatment with different beclomethasone dipropionate formulations: an open-label, randomized comparison of extrafine and conventional aerosols in children","volume":"109","author":"Pedersen","year":"2002","journal-title":"Pediatrics"},{"issue":"13 Suppl","key":"10.1067\/mai.2002.124771a_bib19","first-page":"1","article-title":"International Asthma Management Project","volume":"47","author":"International Consensus Report on Diagnosis and Management of Asthma","year":"1992","journal-title":"Allergy"},{"key":"10.1067\/mai.2002.124771a_bib20","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/thx.49.10.961","article-title":"Delivery of beclomethasone dipropionate from a spacer device: what dose is available for inhalation?","volume":"49","author":"O'Callaghan","year":"1994","journal-title":"Thorax"},{"issue":"suppl A","key":"10.1067\/mai.2002.124771a_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0954-6111(98)90213-X","article-title":"Efficacy of chlorofluorcarbon-free beclomethasone dipropionate 400 \u03bcg day-1 delivered as an extrafine aerosol in adults with moderate asthma","volume":"92","author":"Matthys","year":"1998","journal-title":"Respir Med"},{"key":"10.1067\/mai.2002.124771a_bib22","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/adc.69.2.206","article-title":"Comparison of the efficacy and safety of inhaled fluticasone propionate 200 micrograms\/day in mild and moderate asthma","volume":"69","author":"Gustafsson","year":"1993","journal-title":"Arch Dis Child"},{"key":"10.1067\/mai.2002.124771a_bib23","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/thx.53.8.656","article-title":"Fluticasone propionate 750 \u03bcg\/day versus beclomethasone dipropionate 1500 \u03bcg\/day: comparison of efficacy and adrenal function in paediatric asthma","volume":"53","author":"Fitzgerald","year":"1998","journal-title":"Thorax"},{"key":"10.1067\/mai.2002.124771a_bib24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0022-3476(99)70198-8","article-title":"Efficacy and safety of high-dose inhaled steroids in children with asthma: a comparison of fluticasone propionate with budesonide","volume":"134","author":"Ferguson","year":"1999","journal-title":"J Pediatr"},{"key":"10.1067\/mai.2002.124771a_bib25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/08942680152484126","article-title":"Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants","volume":"14","author":"Richards","year":"2001","journal-title":"J Aerosol Med"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674902000635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674902000635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T08:06:01Z","timestamp":1704528361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674902000635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,7]]}},"alternative-id":["S0091674902000635"],"URL":"https:\/\/doi.org\/10.1067\/mai.2002.124771a","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2002,7]]}}}